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Abstract
Duchenne muscular dystrophy (DMD) is an incurable degenerative muscle disorder. We injected WT mouse induced
pluripotent stem cells (iPSCs) into mdx and mdx:utrophin mutant blastocysts, which are predisposed to develop DMD with
an increasing degree of severity (mdx ,,, mdx:utrophin). In mdx chimeras, iPSC-dystrophin was supplied to the muscle
sarcolemma to effect corrections at morphological and functional levels. Dystrobrevin was observed in dystrophin-positive
and, at a lesser extent, utrophin-positive areas. In the mdx:utrophin mutant chimeras, although iPSC-dystrophin was also
supplied to the muscle sarcolemma, mice still displayed poor skeletal muscle histopathology, and negligible levels of
dystrobrevin in dystrophin- and utrophin-negative areas. Not only dystrophin-expressing tissues are affected by iPSCs. Mdx
and mdx:utrophin mice have reduced fat/body weight ratio, but iPSC injection normalized this parameter in both mdx and
mdx:utrophin chimeras, despite the fact that utrophin was compromised in the mdx:utrophin chimeric fat. The results
suggest that the presence of utrophin is required for the iPSC-corrections in skeletal muscle. Furthermore, the results
highlight a potential (utrophin-independent) non-cell autonomous role for iPSC-dystrophin in the corrections of non-muscle
tissue like fat, which is intimately related to the muscle.
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Introduction
Duchenne muscular dystrophy (DMD) is an X-linked degener-
ative disorder of muscle that affects 1 in 3500 newborn males.
Progressive muscle weakness generally begins in preschool years.
Affected boys are confined to wheelchairs in adolescence, and
mortality in young adulthood results from cardiomyopathy or
respiratory failure [1,2].
Mutations are found in the gene for a 427 Kd dystrophin
protein, which localizes to the sarcolemma of the skeletal muscle.
Dystrophin is the key protein in the dystrophin-glycoprotein
complex (DGC), which includes dystroglycans, sarcoglycans,
dystrobrevin and syntrophin [3]. In the absence of dystrophin,
the DGC is unstable and destroyed. Absence of the DGC results in
mechanically induced damage of the skeletal muscle fibers [4,5,6].
The mdx mice bear a naturally occurring mutation in exon 23
of the dystrophin gene that abrogates expression of the full-length
dystrophin protein, causing symptoms of muscular dystrophy
[7,8]. These mice exhibit moderate signs of skeletal muscle
dystrophy but have nearly normal lifespan. The dystrophin-related
protein utrophin is up-regulated in the sarcolemma of mdx muscle
[9,10,11]. Mutations in both the dystrophin and the utrophin
genes result in a more severe phenotype and premature death
[10,11]. Conversely, activation of utrophin or introduction of
utrophin in mdx by transgenesis or viral delivery produces
significant recoveries [11,12,13,14,15].
Several therapeutic strategies for treatment of DMD have been
investigated [16,17,18,19,20,21,22,23,24,25,26,27]. Induced plu-
ripotent stem cells (iPSCs) are an attractive source for cell-based
therapy, in part because human iPSCs can be reprogrammed from
adult fibroblasts of patients [28,29,30,31,32,33]. Previous studies
in mice show that only a fraction of the muscle must express full-
length dystrophin to confer protection against the development of
DMD, as mice with a mosaic pattern of expression in the skeletal
muscle displayed a markedly milder phenotype than mdx mice
[34]. To create a mosaic model of DMD, we injected WT
embryonic stem cells (ESCs) into mdx blastocysts [35]. ESCs
incorporated at a low percentage to supply sarcolemma-dystro-
phin and to effect corrections. We also injected mdx ESCs into
blastocysts. ESCs incorporated but failed to supply dystrophin and
did not effect corrections [35]. Recently, mdx iPSCs and ESCs
containing an artificial chromosome with a full-length human
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human dystrophin to muscle and heart, but corrective analyses of
the muscle were not performed [36,37]. Here we injected iPSCs
into mdx single mutant and mdx:utrophin double mutant
blastocysts, to generate a mosaic rescue paradigm and to study
the corrective potential of the iPSCs in mild and severe mouse
models of DMD. We show that the iPSCs supply dystrophin to the
sarcolemma to effect corrections in the skeletal muscle of mdx but
not mdx:utrophin. However, the iPSCs produce corrections of fat
mass in both.
Results
iPSCs incorporate globally
We injected mouse WT eGFP-marked iPSCs into mdx,
mdx:utrophin+/2 and mdx:utrophin2/2 blastocysts. We pro-
duced WT/mdx, WT/mdx:utrophin+/2 and WT/mdx:utro-
phin2/2 chimeric mice. WT/mdx and WT/mdx:utrophin+/2
chimeras displayed an identical phenotype, and thus, both
genotypes were grouped under the name of WT/mdx. WT/
mdx:utrophin2/2 chimeras displayed a distinct phenotype from
that of WT/mdx and thus, were named WT/mdx:utrophin. A
total of 10 WT/mdx and 4 WT/mdx:utrophin mice in the range
of 10–30% mosaicism were used in the study. At 1 week of age,
chimeric pups were identified by performing genomic PCR of the
eGFP transgene from DNA of tail biopsies (data not shown). After
sacrifice (10–12 weeks for WT/mdx:utrophin and 12–15 weeks for
WT/mdx), global incorporation was assessed by performing PCR
of the eGFP transgene in fat, liver, lung, spleen, muscle
(quadriceps, pectoralis, diaphragm), tail and heart (Fig. 1A and
data not shown). The degree of chimerism was determined by
performing semi-quantitative genomic PCR of the WT allele of
dystrophin using DNA samples from skeletal muscle, heart and tail
(Fig. 1B for skeletal muscle and data not shown). Unlike the
skeletal muscle, the cardiac muscle does not syncytialize, and
therefore, the percentage of dystrophin-positive cardiac myocytes
represents an accurate measure of the degree of chimerism [35].
Thus, the degree of chimerism was further confirmed by
immunofluorescence (IMF) for dystrophin in heart sections
(Fig. 2) [35]. Dystrophin detection in skeletal muscle was also
verified by dystrophin IMF (Fig. 2 for diaphragm and data not
shown for quadriceps and pectoralis).
Dystrophin is supplied to the chimeric muscle
The iPSCs incorporated into the heart and skeletal muscle of
WT/mdx and WT/mdx:utrophin chimeras and supplied dystro-
phin (Fig. 1c and Fig. 2). As expected, the presence of sarcolemma-
utrophin was observed in the dystrophin-negative fibers of WT/
mdx but not in WT/mdx:utrophin muscle (Fig. 2). No utrophin
was detected in dystrophin-positive (iPSC-derived) fibers in WT/
mdx (Fig. 2). Consistent with lack of sarcolemma-utrophin
upregulation in WT/mdx:utrophin muscle (Fig. 2), negligible
utrophin levels were detected by WB (Fig. 1c). As expected,
utrophin was detected in a portion of the neuromuscular junction
(NMJ) and the axons of WT/mdx:utrophin muscle (Fig. 2H,
insets).
iPSC incorporation increased staining of dystrobrevin (Dbv)
(Fig. 1c), which was found at the sarcolemma of the skeletal muscle
(Fig. 3C and D). Weak sarcolemma-dystrobrevin staining was
observed in areas of undetectable dystrophin (utrophin-positive) in
mdx but not in mdx:utrophin chimeric muscle (Fig. 4C, compare
with 4E). Consistent with co-localization of dystrobrevin and
utrophin, a residual dystrobrevin band was more intense in mdx
than mdx:utrophin muscle (Fig. 1C). Syntrophin was not affected
Figure 1. iPSCs incorporate globally. a) PCR analysis showing that eGFP marker (indicative of iPSCs) is present globally in the WT/mdx chimera;
b) Semi Q genomic PCR using DNA from quadriceps muscle. Note that the intensity of the Dys+ band (indicative of percentage of iPSC chimerism) in
WT/mdx and WT/mdx:utrophin is approximately 1/5 of that observed in WT; c) WB analysis showing dystrophin, utrophin, dystrobrevin and
syntrophin production in the quadriceps. Abbreviations: eGFP: enhanced green fluorescent protein, F: fat, Li: liver, Lu: lung, S: spleen, M: quadriceps
muscle, T: tail, dys+: WT allele of dystrophin, Id+: WT allele of Id1 control (Id1 is present in both iPSC-derived and blastocyst-derived cells, and thus, is
invariant among WT, KO and chimeric groups), Dys: 420 Kd dystrophin, Utr: 420 Kd utrophin, Dbv: 40 Kd (isoform of the dystrophin-dependent)
dystrobrevin-alpha, Synt: 55 Kd syntrophin; Tub: 55 Kd tubulin.
doi:10.1371/journal.pone.0020065.g001
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incorporate in the mdx and mdx:utrophin muscle and supply
dystrophin to the sarcolemma.
Functional corrections
We determined the functional consequences of WT iPSC
incorporation in mdx muscle. To this end, extensor digitorum
longus (EDL) muscle was isolated and subjected to stress tests
(Table 1). Stress output (force/cross sectional area) for tetanic and
twitch contractions from the EDL of WT/mdx were comparable
to that of WT and (ESC-derived) WT/mdx mice [35]. Thus,
both ESCs and iPSCs effect functional corrections in mdx
muscle.
Histological corrections
To study the effect of iPSC on histopathology, we analyzed the
diaphragm, which develops fibrosis and mononuclear invasion
(Fig. 5a) [8]. We also analyzed limb (quadriceps, Fig. 5a) muscles,
which show central nucleation. WT and WT/mdx but not mdx
muscle (diaphragm, quadriceps) show an organized architecture
(fibers of similar size, Fig. 5aE), no central nucleation (,10%,
Fig. 5aF), no mononuclear invasion (Fig. 5aE) and little or no
fibrosis (Fig. 5aG). However, WT/mdx:utrophin muscle (dia-
phragm, quadriceps) show a disorganized architecture (Fig. 5aM),
increased central nucleation (.80%, Fig. 5aN), mononuclear
invasion (Fig. 5aM) and extensive fibrosis though slightly
diminished in comparison to mdx:utrophin (Fig. 5aO). In support
of a lack of correction observed in the absence of utrophin, the
pathological curvature of the spine (kyphosis) observed in
mdx:utrophin mice [10] was still apparent in the WT/
mdx:utrophin chimeras (Fig. 5b). Thus, the iPSCs improve the
pathology in the skeletal muscle of WT/mdx but not to the same
extent in WT/mdx:utrophin mice despite provision of dystrophin
to both.
Fat mass gain
Other tissues were affected by the iPSCs. Mdx and mdx:u-
trophin mice have reduced fat, but their fat was restored in the
chimeras. Abdominal fat weight/body weight of WT/mdx mice
(3.760.5%) or WT/mdx:utrophin (4.160.6%) mice was compa-
rable to that of WT mice (4.261.5%), and was improved relative
to mdx (1.760.6%) or mdx:utrophin mice (0.560.3%)(P,0.05).
Utrophin was detected in the fat (Fig. 6). However, dystrophin was
not (data not shown). In contrast to the ability of iPSCs to supply
dystrophin to the skeletal muscle of mdx:utrophin (Fig. 1C), the
ability of the iPSCs to supply utrophin to the fat of mdx:utrophin
was compromised (Fig. 6). The results indicate that iPSCs effect
corrections outside the muscle.
Discussion
In this report we show that injection of mouse WT iPSCs at pre-
implantation stage produces corrections in mouse models of
muscular dystrophy. A rescue process in muscle and fat depends
on the ability of the iPSCs to produce dystrophin. However, while
the rescue in muscle appears to also depend on the presence of an
intact utrophin gene, the rescue of fat does not.
Figure 2. Dystrophin is supplied to chimeric muscle. WT (A, B),
WT/mdx (C, D) and WT/mdx:utrophin (G, H) heart and diaphragm
muscle display sarcolemma-dystrophin (green staining); WT/mdx (C, D)
and mdx (E, F) heart and diaphragm muscle display sarcolemma-
utrophin (red staining); red arrow: utrophin-positive axon (H inset left);
yellow arrows: utrophin-positive (red)/alpha-BT-positive (green) NMJ (H
inset right); green arrow: utrophin-negative/alpha-BT-positive (green)
NMJ (J inset); blue: nuclear staining (DAPI). Magnification: 1006; H inset
left and right: 2006and 4006respectively; J inset: 4006.
doi:10.1371/journal.pone.0020065.g002
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mutant environment
The iPSCs bear advantages over the ESCs, as human iPSCs can
be reprogrammed from adult cells of human patients. We have
previously shown that ESCs incorporate with widespread tissue
distribution when injected into mdx blastocysts [35,38], but the
chimeric potential of the WT iPSCs when injected into a mutant
blastocyst remained elusive. We show that a mutant environment
does not compromise the capacity of the iPSCs to generate
chimeras with widespread tissue distribution. Like the ESCs [35],
the iPSCs bear a corrective potential.
Corrections of skeletal muscle
Partial incorporation of dystrophin has been shown to correct
the dystrophin-negative muscle, as mdx mice with a mosaic
pattern of dystrophin expression manifest a milder phenotype
[16,18,34,39]. Furthermore, mosaic WT/mdx mice with a portion
of ESC-derived muscle have improved pathology and function
[35]. Here we tested iPSC injection, and report that iPSC-mosaic
mice showed recovery in the skeletal muscle of WT/mdx but not
of WT/mdx:utr chimeras. In the mdx rescue, sarcolemma
utrophin is detected in the iPSC-negative (dystrophin-negative)
muscle fibers. As expected, dystrobrevin is present in iPSC-fibers,
which contain high dystrophin. However, and consistent to
previous results [35], dystrobrevin is also present in fibers
containing low dystrophin (high utrophin) levels. Dystrobrevin
may replace some of the functions of dystrophin to ultimately
stabilize a portion of the DGC [6,40]. It is possible that utrophin
contributes to the stabilization of dystrobrevin in areas with low
dystrophin in mdx chimeras. The notion of utrophin as a DGC
stabilizer in chimeras is strengthened by our findings showing that
a residual dystrobrevin band is more intense in mdx than in
mdx:utrophin muscle. This utrophin-dependent effect appears to
be specific for some members of the DGC, as syntrophin levels are
unaffected by loss of utrophin or dystrophin. The utrophin
mutation in mdx:utrophin chimeras appeared to affect the rescue
process by the iPSCs, as the double mutant chimeras developed an
abnormal fibrotic musculature.
Absence of sarcolemma-utrophin in the iPSC-fibers may reflect
a process of inhibition of iPSC-utrophin by iPSC-dystrophin. On
the other hand, the presence of iPSC-utrophin in NMJ indicates
that the iPSCs are capable of producing utrophin. Thus, inhibition
of iPSC-utrophin by iPSC-dystrophin appears to be sarcolemma-
specific. The development of a fibrotic muscle in mdx:utrophin
chimeras suggests that the presence of iPSC-utrophin in a small
portion of the NMJ and of the axons is insufficient for the
corrective activities.
It is possible that sarcolemma utrophin is required for the
corrections. It is also possible that absence of utrophin from other
compartments inside or outside the muscle plays an indirect role in
the development of the skeletal muscle pathology. The early onset
and rapid progression of the disease, the post-synaptic defects at
the NMJ, the increase in mononuclear infiltration that results in
massive fibrosis and the lack of a healthy pool of myogenic cell
population [10,41,42] may also contribute to the lack of
responsiveness of the mdx:utr muscle to iPSC treatment. It would
be intriguing to determine which are the structures (i.e.
sarcolemma, NMJ, myogenic compartment, fibrosis) that mostly
affect the iPSC rescue in the WT/mdx:utr muscle.
The severe phenotype observed in mdx:utr mice contrasts with
the mild phenotype observed in mdx mice, and this difference is
caused by global absence of utrophin. Thus, global loss of utrophin
and the progressive deterioration of the animal health may be key
contributors to the muscle phenotype of WT/mdx:utr chimeras.
Interestingly, the poor health of the mdx:utr mice does not appear
Figure 3. Dystrobrevin is supplied to chimeric muscle. WT (A), WT/mdx (C) and WT/mdx:utr (D) diaphragm muscle display sarcolemma-
dystrobrevin (green staining); mdx (B) and WT/mdx (C) diaphragm muscle display sarcolemma-utrophin (red staining); blue: nuclear staining (DAPI);
magnification: 2006.
doi:10.1371/journal.pone.0020065.g003
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mdx:utr tissues respond differently to the iPSC rescue.
It is possible that a higher degree of chimerism (i.e. WT/
mdx:utrophin chimeras with greater than 30% iPSC mosaicism)
will increase dystrophin supply and lead to corrections in muscle.
Nevertheless, it is clear from the studies of the mdx and
mdx:utrophin chimeric mice that the presence of utrophin in the
chimeras is beneficial for the development of a healthy chimeric
muscle.
Sarcolemma-dystrophin versus -utrophin: is it a matter of
choice?
In the WT sarcolemma, the presence of dystrophin precludes
the activation of utrophin. In the mdx sarcolemma, the obligatory
absence of dystrophin permits up-regulation of utrophin. In the
mdx:utrophin muscle, neither protein is produced. In the WT/
mdx:utrophin muscle, the iPSCs may supply: (a) dystrophin but
not utrophin, (b) utrophin but not dystrophin, (c) both or (d) none.
The WT iPSC-derived fibers, surrounded by mutant fibers
Figure 4. Utrophin sustains weak dystrobrevin staining. Dystrobrevin (A) is detected in WT quadriceps muscle; weak dystrobrevin (C) and
utrophin (D) are detected in WT/mdx quadriceps muscle areas with undetectable dystrophin (D inset); no dystrobrevin (E) and no utrophin (F) are
detected in WT/mdx:utrophin quadriceps muscle areas with undetectable dystrophin (F inset); Abbreviation: utr: utrophin; blue: nuclear staining
(DAPI); magnification: 2006.
doi:10.1371/journal.pone.0020065.g004
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phin but not utrophin. This indicates that the sequence:
dystrophin as first choice, utrophin as second choice (in the
absence of dystrophin) takes place not only in WT muscle but also
in mosaic muscle containing WT iPSC-fibers. The mutant
environment does not appear to modify the hierarchy of events
that governs dystrophin/utrophin production. Future studies with
mdx iPSCs aimed at supplying utrophin but not dystrophin will
help further delineate the regulatory circuitry that exists between
dystrophin and utrophin.
Table 1. Contractile stress recovery in WT/mdx EDL muscle.
Genotype tetanus (g/mm
2) twitch (g/mm
2)
WT 48.462.0 7.260.3
WT/mdx* 43.961.0 6.560.1
Mdx 24.467.3 3.260.3
*P,0.05 relative to mdx.
doi:10.1371/journal.pone.0020065.t001
Figure 5. WT/mdx but not WT/mdx:utrophin mice show improved muscle pathology. a) H&E staining of diaphragm and quadriceps
muscles of WT (A, B), WT/mdx (E, F), mdx (I, J), WT/mdx:utrophin (M, N) and mdx:utrophin (Q, R) mice; Masson trichrome staining of diaphragm and
quadriceps muscles of WT (C, D), WT/mdx (G, H), mdx (K, L), WT/mdx:utrophin (O, P) and mdx:utrophin (S, T) mice; b) kyphosis in mdx:utrophin (B) and
WT/mdx:utrophin (C) but not in mdx (A) mice; magnification: 2006(a) and 46(b).
doi:10.1371/journal.pone.0020065.g005
iPSC-Correction of Muscular Dystrophy Mice
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Intriguingly, iPSCs (and ESCs, [35]) appeared to effect
corrections in fat, which does not express dystrophin but does
express utrophin. Unlike mdx mice, which have reduced fat, we
previously showed that ESC-chimeras regain normal fat mass [35].
The fat recovery depends on the presence of dystrophin, as mdx
ESCs (lacking dystrophin) cannot exert corrections in muscle or fat
tissues [35]. The fat recovery highlights a non-cell autonomous role
of dystrophin, perhaps via paracrine factors that may bridge
dystrophin-expressing tissues (heart, skeletal and smooth muscle)
with dystrophin-non-expressing tissues (fat). The fat recovery gains
significance in light of our recent finding that shows upregulation of
muscular markers in the mdx and WT/mdx fat, like troponin,
tropomyosin and myosin genes [35], and another recent discovery
that links brown fat to muscle via a Myf5 common ancestor that has
interconvertible properties [43,44,45,46].
The process of inhibition of utrophin by dystrophin in the
muscle sarcolemma does not appear to operate in the fat, because
(a) dystrophin is not present in the fat, and (b) utrophin is produced
in fat of mice that produce dystrophin in muscle. The latter
observation indicates that dystrophin does not control utrophin
expression at a distance. Importantly, the fat of mdx and
mdx:utrophin chimeras show mass recovery. The potential of
iPSCs to recover fat in mdx:utrophin contrasts with the ability to
recover skeletal muscle in mdx:utrophin. While the role of
utrophin in the fat remains to be elucidated, it is clear from the
present study that utrophin is not required for the recovery of fat.
We can not formally rule out however that a minimal presence of
utrophin supplied by the iPSC-fat or by other distant structures
(i.e. iPSC-axons, -NMJ) triggers corrective activities in the fat of
mdx:utrophin chimeras.
Is there any reciprocal effect of utrophin-fat to the skeletal
muscle? It is possible that the presence of utrophin in the fat may
indirectly impact the chimeric skeletal muscle to partially stabilize
the DGC with low dystrophin content to additionally contribute to
its key role in the muscle. Because the recovered fat of the
mdx:utrophin chimeras has little utrophin, smaller contribution
from the fat to the rescue of the skeletal muscle of the
mdx:utrophin chimeras may be expected.
Taken together, the results suggest that iPSC-dystrophin from a
distance exerts trophic changes in the fat. The potential non-cell
autonomous role for dystrophin, perhaps via signaling, does not
appear to depend on utrophin mutation.
Conclusion
WT murine iPSCs incorporate at low percentages but globally
into mdx and mdx:utrophin mice when the cells are injected at
blastula stage. The iPSCs rescue the skeletal muscle in mdx but not
in the mdx:utrophin chimeras. An interrelated tissue that does not
express dystrophin, like the fat, responds to the iPSC-based rescue
in an utrophin-independent manner.
The blastocyst assay highlights an important requirement for
utrophin that cannot be circumvented by a low percentage of
dystrophin supply. The assay also highlights the importance of
widespread delivery of dystrophin and the potential roles that
dystrophin may play outside the muscle. Thus, blastocyst injection
of iPSCs represents an important approach to study global
mechanisms of disease corrections in DMD.
Materials and Methods
Induced pluripotent stem cells
(Oct4)-eGFP-marked WT mouse iPSCs were generously
provided by Rudolf Jaenisch at the Whitehead Institute for
Biomedical Research affiliated with Massachusetts Institute of
Technology. WT mouse iPSCs cells grow in DMEM with high
glucose, 15% FCS, glutamine, nonessential aminoacids, beta-
mercaptoethanol, antibiotics and on SNLa76/7 STO cells, which
constitutively express LIF.
Mouse colonies
Mdx mice were purchased from Jackson lab. The colony was
maintained by crossing mdx males with mdx females. Mdx:u-
trophin+/2 mice were generously provided by R. Grange. The
colony was maintained by crossing mdx:utrophin+/2 males with
mdx:utrophin+/2 females. All animal experiments were approved
by the Institutional Animal Care and Use Committee (IACUC) of
the University of Medicine and Dentistry of New Jersey (Animal
Welfare Assurance Number: A3158-01).
Generation of chimeric mice
3–4 week old mdx, mdx:utrophin+/2 and mdx:utrophin2/2
females were superovulated (PMSG and HCG, 5 IU, VWR) and
mated with mdx:utrophin+/2 males. Blastocysts were collected at
3.5 days after mating and injected with 10–14 WT iPSCs. Injected
blastocysts were then transferred into the uteri of pseudopregnant
females and allowed to develop to term. Chimeric pups were
initially identified by genomic PCR for the eGFP transgene in tail
biopsies from 7 day-old pups. Global iPSC incorporation was later
confirmed at time of sacrifice (10–12 weeks for WT/mdx:utrophin
and 12–15 weeks for WT/mdx) by genomic PCR for eGFP on tail,
skeletal muscle (quadriceps), fat, liver, lung and spleen. Degree of
chimerism was determined by semi-quantitative genomic PCR of
the WT allele for dystrophin using DNA samples from skeletal
muscle and by dystrophin IMF on heart cryosections as described
below.
Semi quantitative genomic PCR
Genomic DNA from all chimeras, WT, mdx and mdx:utrophin
controls was isolated from heart, tail, quadriceps, pectoralis and
diaphragm by overnight digestion in SDS/Proteinase K buffer
followed by phenol/chloroform extraction. 50 ng of genomic
DNA was used in PCR with primers for genotyping the WT allele
of dystrophin (Primers: forward–gtcactcagatagttgaagccatttag &
reverse– catagttattaatgcatagatattcag). 2 ng of the same DNA was
used in PCR with Id1 [47] and GAPDH control primers
(Clontech) for internal control. PCR was performed with puRe-
Taq Ready-To-Go PCR beads (GE Healthcare) in the log phase
Figure 6. Utrophin is produced in the fat. WB analysis showing
utrophin production in the fat of WT, WT/mdx and mdx mice. Utrophin
production in the skeletal muscle of mdx is shown as control.
Abbreviations: Utr: utrophin; Tub: tubulin; Quad: quadriceps muscle.
doi:10.1371/journal.pone.0020065.g006
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Variable Mode Imager (Molecular Dynamics), and quantitation
done using ImageQuant [35].
Histology, IMF, and Western Blot (WB)
IMF for dystrophin (1:20, dys2 Novocastra), utrophin (1:1000,
generously supplied by Dr. Fritschy, University of Zurich), Dbv-
alpha (1:200, 610766, BD Transduction Laboratories), syntrophin
(1:100, MA1-745, ABR) and alpha-bungarotoxin (1:250, Invitro-
gen) was performed on 10 mm thick cryosections of heart and
diaphragm. Nuclei were identified with DAPI (Vector Labs).
WB was performed using antibodies reactive with dystrophin
(dys1, Novocastra), utrophin (MANCHO3, clone8a4s, Develop-
mental Studies Hybridoma Bank), dystrobrevin-alpha and syn-
trophin. A 4–20% gradient acrylamide gel and high molecular
weight protein standards (HiMark, Invitrogen and Precision Plus,
Biolab) were used. The intensities of the WB exposures were
quantified using Quantity One software on a GS800-Densitometer
(Bio-Rad). The relative expression levels were normalized using
tubulin bands within the same linear range of detection.
Visualization of fibrosis was performed using a Masson Trichrome
stain kit (Richard-Allan Scientific) on 6 mm thick paraffin-
embedded sections of heart, quadriceps and diaphragm. H&E
was also performed on paraffin sections of heart, quadriceps and
diaphragm to visualize cell morphology and pathology.
Functional analysis
12-week old WT/mdx, mdx, and WT animals were deeply
anesthetized (2 mg xylazine-20 mg ketamine/100 g body mass ip).
Both fast-twitch extensor digitorum longus (EDL) muscles were
excised and incubated at 30uC in an oxygenated (95% O2–5%
CO2) physiological salt solution (PSS; pH 7.6) containing (in mM)
120.5 NaCl, 4.8 KCl, 1.2 MgSO4, 20.4 NaHCO3, 1.6 CaCl2, 1.2
NaH2PO4, 10.0 dextrose, and 1.0 pyruvate. Silk suture (4-O) was
tied to the distal and proximal tendons of the EDL at the
myotendinous junctions. Muscles were then fixed between a clamp
at the base of the bath and arm of a dual-mode servomotor system
(300B, Aurora Scientific), or an isometric force transducer (Grass
FT03), at a resting tension (L0) of 1.0 g. EDL muscles were
maintained at L0 by a stepper motor [48]. The servomotor arm,
stepper motor and electrical stimulator were controlled by
Dynamic Muscle Control software (DMC Version 4.1.6, Aurora
Scientific) to obtain isometric force data. Isometric twitch and
tetanic data were obtained. Length of the muscles was obtained
with a micrometer; each muscle was weighed to the nearest
0.1 mg using an A-200D electronic analytical balance (Denver
Instruments, Denver, Colorado) and then muscles were snap
frozen in liquid nitrogen for subsequent sectioning and WB
analysis. Muscle cross-sectional area (CSA) was determined as
previously described [49]. Twitch and tetanic forces were
normalized to muscle CSA to obtain twitch and tetanic stress
(g/mm2). As every muscle has a distinct pattern of iPSC
incorporation in a chimera, the values obtained from the 2 EDL
muscles from the same WT/mdx animal (n=2) were indepen-
dently considered, and thus, n=4 per WT/mdx group [35].
Data analysis
Results are presented as mean 6 s.e.m or as a range. Statistical
comparison was performed with nonparametric two-tailed un-
paired analysis of variance. A probability value of ,0.05 was
considered to be statistically significant.
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